Login / Signup

Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.

Roger SunMarvin LerousseauJade Briend-DiopEmilie RoutierSeverine RoyTheophraste HenryKanta KaRui JiangNawal TemarAlexandre CarréAdrien LavilleAnthony HamaouiPierre-Antoine LaurentAngela RouyarCharlotte RobertCaroline RobertEric Deutsch
Published in: Journal for immunotherapy of cancer (2022)
These results confirm the predictive value at a lesion level of the biologically inspired CD8 radiomics score in melanoma patients treated with anti-PD1-based immunotherapy and may be interesting to assess the disease spatial heterogeneity to evaluate the patient prognosis with potential clinical implication such as tumor selection for focal ablative therapies.
Keyphrases